Agilent Technologies, Inc. (A)
After hours:
- Business Wire
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer
SANTA CLARA, Calif., May 10, 2022--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with KEYTRUDA® (pembrolizumab) may be appropriate.1 KEYTRUDA is an anti-PD-1 therapy developed by Merck (known as MSD outside the U.S. and Canada). In Europe, KEYTRUDA, in combination with chemotherapy with or wi
- Zacks
Cognex Corporation (CGNX) Q1 Earnings and Revenues Top Estimates
Cognex Corporation (CGNX) delivered earnings and revenue surprises of 7.69% and 2.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Wolfspeed (WOLF) Reports Q3 Loss, Misses Revenue Estimates
Wolfspeed (WOLF) delivered earnings and revenue surprises of 14.29% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
